Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D

Following up the open initiative of anti-malarial drug discovery, a GlaxoSmithKline (GSK) phenotypic screening hit was developed to generate hydroxyethylamine based plasmepsin (Plm) inhibitors exhibiting growth inhibition of the malaria parasite Plasmodium falciparum at nanomolar concentrations. Lea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zogota, Rimants, Kinena, Linda, Withers-Martinez, Chrislaine, Blackman, Michael J., Bobrovs, Raitis, Pantelejevs, Teodors, Kanepe-Lapsa, Iveta, Ozola, Vita, Jaudzems, Kristaps, Suna, Edgars, Jirgensons, Aigars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editions Scientifiques Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336538/
https://www.ncbi.nlm.nih.gov/pubmed/30529637
http://dx.doi.org/10.1016/j.ejmech.2018.11.068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336538/
https://www.ncbi.nlm.nih.gov/pubmed/30529637
http://dx.doi.org/10.1016/j.ejmech.2018.11.068

Ejemplares similares